Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $11.86 Average Target Price from Analysts

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has received an average rating of “Buy” from the eleven analysts that are currently covering the stock, Marketbeat Ratings reports. Eight analysts have rated the stock with a buy rating and three have issued a strong buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $12.6667.

CATX has been the subject of a number of research analyst reports. B. Riley Financial reduced their price objective on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, November 18th. Wedbush reissued an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 30th. UBS Group reaffirmed a “buy” rating and issued a $7.00 price objective (down from $18.00) on shares of Perspective Therapeutics in a report on Friday, November 21st. Piper Sandler initiated coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price objective on the stock. Finally, Truist Financial began coverage on shares of Perspective Therapeutics in a research report on Monday, November 24th. They issued a “buy” rating and a $12.00 target price for the company.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN CATX opened at $5.06 on Tuesday. The business’s 50 day moving average price is $3.64 and its two-hundred day moving average price is $3.28. Perspective Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.66.

Institutional Investors Weigh In On Perspective Therapeutics

Several institutional investors have recently made changes to their positions in CATX. Vanguard Group Inc. increased its stake in Perspective Therapeutics by 5.0% during the 3rd quarter. Vanguard Group Inc. now owns 3,437,865 shares of the company’s stock worth $11,792,000 after acquiring an additional 163,532 shares during the period. Avidity Partners Management LP grew its holdings in shares of Perspective Therapeutics by 7.2% during the 4th quarter. Avidity Partners Management LP now owns 3,210,733 shares of the company’s stock worth $8,830,000 after purchasing an additional 216,700 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Perspective Therapeutics by 15.8% during the 2nd quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock worth $4,758,000 after purchasing an additional 188,887 shares in the last quarter. Opaleye Management Inc. bought a new position in shares of Perspective Therapeutics in the fourth quarter worth $3,257,000. Finally, State Street Corp raised its stake in Perspective Therapeutics by 3.3% in the fourth quarter. State Street Corp now owns 1,141,247 shares of the company’s stock valued at $3,138,000 after purchasing an additional 36,543 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.